Core Viewpoint - The hepatitis concept sector has experienced a decline of 1.54%, ranking among the top declines in concept sectors, with notable declines in stocks such as Hanyu Pharmaceutical, New Sky Pharmaceutical, and Guangsheng Tang [1][2]. Sector Performance - The hepatitis concept sector saw a net outflow of 3.611 billion yuan, with 120 stocks experiencing net outflows, and 7 stocks seeing outflows exceeding 100 million yuan [2]. - The leading stocks in terms of net outflow include Hanyu Pharmaceutical with 256 million yuan, followed by Guangsheng Tang, Tonghua Jinma, and Zhendong Pharmaceutical with outflows of 189 million yuan, 159 million yuan, and 153 million yuan respectively [2][3]. Stock Performance - Among the stocks in the hepatitis concept sector, Hanyu Pharmaceutical declined by 8.91%, Guangsheng Tang by 6.56%, and Tonghua Jinma by 4.15% [3][4]. - Conversely, stocks such as Rejing Bio, Chengyi Pharmaceutical, and Furu Pharmaceutical saw increases of 10.97%, 5.41%, and 4.50% respectively [1][7]. Capital Flow - The main stocks with net inflows include Qianhong Pharmaceutical, Hailan Pharmaceutical, and Puni Testing, with inflows of 129 million yuan, 48.48 million yuan, and 24.35 million yuan respectively [2][7]. - The overall trend indicates a significant capital outflow from the hepatitis concept sector, reflecting investor sentiment and market dynamics [2][3].

天眼查商业履历信息显示，通化金马药业集团股份有限公司，成立于1993年，位于通化市，是一家以从 事医药制造业为主的企业。企业注册资本96649.4707万人民币，实缴资本96649.4707万人民币。公司法 定代表人为张玉富。 通过天眼查大数据分析，通化金马药业集团股份有限公司共对外投资了25家企业，参与招投标项目5000 次，知识产权方面有商标信息57条，专利信息34条，此外企业还拥有行政许可258个。 来源：金融界 金融界消息 截至2025年8月5日收盘，通化金马（000766）报收于23.16元，上涨0.09%，换手率1.95%， 成交量18.81万手，成交金额4.36亿元。 资金流向方面，今日主力资金净流出2171.97万元，占比成交额4.99%。其中，超大单净流出1706.29万 元、占成交额3.92%，大单净流出465.69万元、占成交额1.07%，中单净流出流入755.59万元、占成交额 1.73%，小单净流入1416.38万元、占成交额3.25%。 通化金马最新一期业绩显示，截至2025一季报，公司营业总收入2.99亿元、同比增长1.25%，归属净利 润1158.28万元，同比增长26.09% ...

Core Insights - The CSI 1000 Healthcare Index has shown significant growth, with a 13.89% increase over the past month, 24.30% over the last three months, and 27.10% year-to-date [1] Group 1: Index Performance - The CSI 1000 Healthcare Index is currently at 13651.50 points [1] - The index is designed to provide a diversified investment option by selecting liquid and representative securities from each industry [1] Group 2: Index Holdings - The top ten weighted stocks in the CSI 1000 Healthcare Index include: - Borui Pharmaceutical (3.51%) - Tonghua Golden Horse (2.65%) - Zai Lab (2.51%) - Zhongsheng Pharmaceutical (1.75%) - Zhaoyan New Drug (1.70%) - Anke Biotechnology (1.66%) - Yipinhong (1.63%) - Zuoli Pharmaceutical (1.59%) - Furuide (1.39%) - Dongcheng Pharmaceutical (1.33%) [1] - The index's market distribution shows that the Shanghai Stock Exchange accounts for 55.62%, while the Shenzhen Stock Exchange accounts for 44.38% [1] Group 3: Industry Composition - The industry composition of the CSI 1000 Healthcare Index is as follows: - Chemical drugs: 36.28% - Medical devices: 19.30% - Traditional Chinese medicine: 17.00% - Biological drugs: 14.30% - Medical commerce and services: 7.16% - Pharmaceutical and biotechnology services: 5.94% [2] Group 4: Sample Adjustment - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - In special circumstances, the index may undergo temporary adjustments [2] - When a sample company is delisted, it will be removed from the index, and any mergers, acquisitions, or splits will be handled according to maintenance guidelines [2]

通化金马（000766.SZ）8月4日在投资者互动平台表示，您好，公司新药目前处于正常的审评过程中。 新药在审评过程中出现暂停等情形是新药专业和综合审评过程中的正常状态。此过程中公司积极与CDE 保持沟通，回复相关材料。新药琥珀八氢氨吖啶片审评进展请以药审中心公示信息为准，公司将根据进 展情况及时履行信息披露义务。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：董秘您好！贵司琥珀八汀安吖啶片恢复评审后是否还 需要发补？能不能趁着这次暂停就把材料一次性补齐？ ...

Core Points - The company is Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd, established in 1993 and registered in Jilin Province, China [4][6][7] - The company aims to build a health industry chain and ecosystem, contributing to the modernization and internationalization of the national health industry while maximizing shareholder returns [9] - The registered capital of the company is RMB 966,494,707 [7] Chapter Summaries Chapter 1: General Principles - The company is established to protect the rights of shareholders, employees, and creditors, following the Company Law and Securities Law of the People's Republic of China [4] - The company has undergone several changes in its registration and licensing, including a name change to Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd in 2000 [6][7] Chapter 2: Business Objectives and Scope - The business objectives include serving human health and contributing to the health industry [9] - The business scope includes manufacturing various pharmaceutical forms, research and development of traditional Chinese medicine, and medical project investments [9] Chapter 3: Shares - The company issues shares in the form of stocks, with a total of 966,494,707 shares issued, all being ordinary shares [10][21] - The company follows principles of fairness and transparency in share issuance [10] Chapter 4: Shareholders and Shareholder Meetings - Shareholders have rights to dividends, attend meetings, and supervise company operations [16] - The company must hold annual shareholder meetings within six months after the end of the fiscal year [25] Chapter 5: Board of Directors - The board of directors is responsible for the company's management and must act in the best interest of the company and its shareholders [18] - The company has provisions for independent directors and committees within the board [18] Chapter 6: Senior Management - Senior management includes the general manager, deputy general managers, and other key personnel [8] Chapter 7: Financial Accounting System, Profit Distribution, and Auditing - The company must adhere to a financial accounting system and undergo internal audits [8] Chapter 8: Notices and Announcements - The company is required to issue notices and announcements as per legal requirements [8] Chapter 9: Mergers, Divisions, Capital Increases, Reductions, Dissolution, and Liquidation - The company can merge, divide, increase or reduce capital, and dissolve according to legal procedures [8] Chapter 10: Amendments to the Articles - The company can amend its articles of association following the prescribed procedures [8] Chapter 11: Supplementary Provisions - The articles of association serve as a binding document for the company, shareholders, directors, and senior management [8]

General Principles - The rules aim to clarify the responsibilities and authority of the board of directors of Tonghua Jinma Pharmaceutical Group Co., Ltd, ensuring efficient decision-making and compliance with relevant laws and regulations [1][2][3] Board of Directors - The board is a permanent institution responsible for the company's development goals and major operational decisions, accountable to the shareholders' meeting [2][3] - Directors must be natural persons and cannot hold office under certain disqualifying conditions, such as criminal convictions or bankruptcy responsibilities [4][5] - Directors are elected by the shareholders' meeting for a term of three years and may be re-elected [3][6] Duties and Obligations - Directors have a duty of loyalty to the company, which includes avoiding conflicts of interest and not misappropriating company assets [6][7] - Directors must act diligently and in the best interest of the company, ensuring compliance with laws and regulations [7][8] Board Composition and Powers - The board consists of nine directors, including three independent directors, and is led by a chairman [7][8] - The board has the authority to convene shareholder meetings, formulate profit distribution plans, and make significant operational decisions [8][9] Board Meetings - The board must hold at least two meetings annually, with specific procedures for calling and conducting meetings [12][13] - Decisions require a majority vote from attending directors, and independent directors have specific voting rights in related party transactions [14][15] Secretary of the Board - The company appoints a secretary responsible for coordinating information disclosure and managing investor relations [10][11] - The secretary must possess relevant professional knowledge and is accountable for maintaining confidentiality regarding company secrets [10][11] Record Keeping - The board must maintain detailed records of meetings, including attendance, agenda items, and voting results, which are preserved for at least ten years [17][18]

通化金马药业集团股份有限公司 章 程 （2025 年 6 月 23 日经公司 2024 年年度股东大会审议通过） 2025 年 6 月 — 1 — 目 录 — 2 — 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东和股东会 第一节 股东的一般规定 第二节 控股股东和实际控制人 第三节 股东会的一般规定 第四节 股东会的召集 第五节 股东会的提案与通知 第六节 股东会的召开 第七节 股东会的表决和决议 第五章 董事和董事会 第一节 董事的一般规定 第二节 董事会 第三节 独立董事 第四节 董事会专门委员会 第六章 高级管理人员 第七章 财务会计制度、利润分配和审计 — 3 — 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第八章 通知和公告 第一节 通知 第二节 公告 第九章 合并、分立、增资、减资、解散和清算 第一节 合并、分立、增资和减资 第二节 解散和清算 第十章 修改章程 第十一章 附则 第一章 总则 第一条 为维护本公司、股东、职工和债权人的合法权益，规范公司的组织和行 为，根据《中华人民共和国公司法》 ...

通化金马药业集团股份有限公司 股东会议事规则 （2025 年 6 月 23 日经公司 2024 年年度股东大会审议通过） 第一章 总则 第一条 为规范通化金马药业集团股份有限公司(以下简称"公司")的行为， 保证股东依法行使职权，维护股东的合法权益，根据《中华人民共和国公司法》 (以下简称"《公司法》")《通化金马药业集团股份有限公司章程》(以下简称 "《公司章程》")及其他有关法律、法规、规范性文件之规定制定本规则。 第二条 公司应当严格按照法律、行政法规、本规则及公司章程的相关规定 召开股东会,保证股东能够依法行使权利。 公司董事会应当切实履行职责,认真、按时组织股东会。公司全体董事应当 勤勉尽责,确保股东会正常召开和依法行使职权。 第三条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第四条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次, 应当于上一会计年度结束后的 6 个月内举行。临时股东会不定期召开,出现《公 司法》第一百一十三条规定的应当召开临时股东会的情形时,临时股东会应当在 2 个月内召开。 公司在上述期限内不能召开股东会的,应当报告公司所在地中国证券监督管 理委员会 ...

通化金马药业集团股份有限公司 董事会议事规则 （2025 年 6 月 23 日经公司 2024 年年度股东大会审议通过） 第一章 总则 第一条 为明确通化金马药业集团股份有限公司（以下简称"公司"）董事 会的职责权限，规范董事会的组织和行为，确保董事会的工作效率和科学决策， 根据《中华人民共和国公司法》（以下简称"公司法"）、《上市公司治理准则》、 《深圳证券交易所股票上市规则》和《通化金马药业集团股份有限公司章程》（以 下简称"公司章程"）的规定，制定本规则。 第二条 董事会是公司的常设机构，维护公司和全体股东的利益，负责公司 发展目标和重大经营活动的决策。 （六）被中国证监会采取证券市场禁入措施，期限未满的； 第三条 董事会对股东会负责，执行股东会决议。 第二章 董事 第四条 公司董事为自然人，有下列情形之一的，不能担任公司的董事： （一）无民事行为能力或者限制民事行为能力； （二）因贪污、贿赂、侵占财产、挪用财产或者破坏社会主义市场经济秩序， 被判处刑罚，或者因犯罪被剥夺政治权利，执行期满未逾 5 年，被宣告缓刑的， 自缓刑考验期满之日起未逾 2 年； （三）担任破产清算的公司、企业的董事或者厂长、经理 ...

证券代码：000766 证券简称：通化金马 公告编号：2025-29 通化金马药业集团股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会无否决提案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、召开时间： 现场会议召开时间为：2025年6月23日下午14:30 网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025年6月23日9:15—9:25，9:30—11:30和13:00—15:00；通过互联网投票系统 进行网络投票的具体时间为2025年6月23日上午9:15至下午15:00期间的任意时 间。 2、召开地点：吉林省通化市二道江区金马路999号，公司七楼会议室。 3、召开方式：采用现场表决与网络投票相结合的方式召开 4、召集人：公司董事会 5、现场会议主持人：董事长张玉富先生 6、会议召开的合法、合规性：本次会议的召集、召开与表决程序符合《公 司法》《上市公司股东会规则》《深圳证券交易所股票上市规则》等有关法律、行 政法 ...